PCP
CAI icon

Perbak Capital Partners’s Caris Life Sciences CAI Stock Holding History

Perbak Capital Partners’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,001
Closed -$393K – 289
2026
Q1 		$393K Buy
22,001
+14,150
+180% +$309K 0.1% 230
2025
Q4 		$212K Sell
7,851
-2,852
-27% -$80.3K 0.06% 212
2025
Q3 		$324K Buy
+10,703
New +$341K 0.06% 266

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Perbak Capital Partners's CAI Position: Q2 2026 in Review

Perbak Capital Partners sold out of Caris Life Sciences (CAI) in Q2 2026, closing a stake of 22,001 shares — an estimated $393K sold.

Perbak Capital Partners first reported a position in CAI in Q3 2025 and held it in 3 quarters. The position peaked at $393K in Q1 2026. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Perbak Capital Partners reported no remaining Caris Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 22,001 Caris Life Sciences shares in Q2 2026, an estimated $393K.
  • Perbak Capital Partners first reported a position in Caris Life Sciences in Q3 2025 and held it in 3 quarters.
  • Perbak Capital Partners's Caris Life Sciences position peaked at $393K in Q1 2026.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.